According to filings with the U.S. Securities and Exchange Commission, SyntheX is raising up to $5,175,000.00 in new funding. Sources indicate that as part of senior management Senior Executive, Charly Chahwan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About SyntheX
SyntheX uses synthetic biology to create the next generation of drug discovery platforms. Using genetically engineered circuits, we rely on intracellular drug selection as opposed to in-vitro screening. This allows us to discover unbiased compounds with novel modes of action that can engage targets in either competitive or allosteric ways. We have developed ToRPPIDO to discover disruptors of protein-protein interactions (PPIs), and ToRNeDO to discover functional molecular glues for degraders of a neosubstrate of interest with a desired E3 ligase. In the same cells, we incorporate our proprietary DNA-encoded libraries of peptides and macrocycles to enable the production and selection of molecules in an efficient and high throughput manner. Our lead programs focus on oncology.

To learn more about SyntheX, visit http://www.synthexlabs.com/

Contact:
Charly Chahwan, Senior Executive
415-706-8701
https://www.linkedin.com/in/charly-chahwan-86275b116/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.